Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype

Breast Cancer Research and Treatment

Volumn 88, Issue 3, 2004, Pages 197-204

  Grieu, Fabienne ^a   Wei, Qi Li ^b   Iacopetta, Barry ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Breast cancer; Matrix metalloproteinase; Polymorphism

Indexed keywords

ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HISTOLOGY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENOTYPE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 12344313155     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-0595-6     Document Type: Article

References (34)

1. Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 36: 1621-1630, 2000
2. Westermarck J, Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999
3. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287-293, 1999
4. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65: 55-61, 2001
5. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89: 1270-1275, 2003
6. Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 77: 85-91, 2003
7. Garbett EA, Reed MW, Brown NJ: Proteolysis in human breast and colorectal cancer. Br J Cancer 81: 287-293, 1999
8. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87: 602-611, 1996
9. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinicopathological correlations. Clin Exp Metastasis 16: 577-585, 1998
10. Lee KS, Rha SY, Kim SJ, Kim JH, Roh JK, Kim BS, Chung HC: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 14: 512-519, 1996
11. Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS: MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77: 145-155, 2003
12. Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix- metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 435: 566-573, 1999
13. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189: 161-168, 1999
14. Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt HJ, Hristic M, Berclaz G, Ziemiecki A, Andres AC: Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol 21: 25-30, 2000
15. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart M: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 424: 641-645, 1994
16. Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Chung HC: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5: 875-879, 1998
17. Rha SY, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Chung HC: Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat 43: 175-181, 1997
18. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I: A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10: 1057-1063, 2004
19. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751, 2003
20. La Rocca GL, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S: Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90: 1414-1421, 2004
21. Price SJ, Greaves DR, Watkins H: Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276: 7549-7558, 2001
22. Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D: Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25: 399-404, 2004
23. Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62: 6430-6433, 2002
24. Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D: A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63: 3987-3990, 2003
25. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794, 1999
26. Jones GT, Phillips VL, Harris EL, Rossaak JI, van Rij AM: Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg 38: 1363-1367, 2003
27. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B: Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23: 311-315, 2002
28. Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen AP, Iacopetta BJ, Berns EM: Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J Clin Endocrinol Metab 88: 1653-1657, 2003
29. Iacopetta B, Grieu F, Joseph D: The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 90: 419-422, 2004
30. Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, Robbins PD: Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642-647, 1997
31. Grieu F, Joseph D, Norman P, Iacopetta B: Development of a rapid genotyping method for single nucleotide polymorphisms and its application in cancer studies. Oncol Rep 11: 501-504, 2004
32. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P: Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40: 43-48, 2002
33. Giannelli G, Pozzi A, Stetler-Stevenson WG, Gardner HA, Quaranta V: Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am J Pathol 154: 1193-1201, 1999
34. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA: Linked common polymorphisms in the gelatinase A promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 278: 20490-20499, 2003